Apellis Pharmaceuticals, Inc.

Contributing Author

Recent Articles by Apellis Pharmaceuticals, Inc.

Jul-31	Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results APLS GlobeNewswire
Jul-28	FDA Approves Apellis' EMPAVELI (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older APLS GlobeNewswire
Jul-24	Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results APLS GlobeNewswire
Jul-15	Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting APLS GlobeNewswire
Jul-01	Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli (systemic pegcetacoplan) APLS GlobeNewswire
Jun-04	Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference APLS GlobeNewswire
May-07	Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results APLS GlobeNewswire
May-06	Apellis Pharmaceuticals to Present at Upcoming Investor Conferences APLS GlobeNewswire